Clinical Trial Search

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Overall Satisfaction With Assigned Treatment on the Treatment Satisfaction Survey — 4.1; 3.7 units on a scale — p=0.0088

Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period…

Primary: Maximum Measured Concentration of BI 409306 in Plasma (Cmax) — 183; 175; 150 Nanomole per litre

Primary: Event Free Survival (EFS) Per Blinded Central Assessment — 8.3; 2.0 months — p=<0.0001

Primary: Difference in Glucose Tolerance Between Morning at 7:00 AM and Evening at 7:00 PM — 163; 203 mg/dl — p=0.02

Primary: Numerical Rating Scale (NRS) Pain on Walking — -2.48 score on a scale — p=<0.0001

Primary: Number of Participants With Serious Adverse Events (SAE) at Least Possibly Related to ADVATE — 0 Participants

Primary: Clinical Benefit Rate at 24 Weeks — 3; 18; 9 Participants

Primary: Incidence Rate of Fatal or Non-fatal Major Bleeding — 26; 52; 41; 52 Events per 1,000 person-years — p=<0.0001

Primary: Mass Balance Recovery of Total Radioactivity in Urine and Faeces: Amount Excreted Within the Time Interval From 0 to the Time of the Last Quantifiable Data Point as a…

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 83.3; 50.0; 100; 50.0 percentage of participants

Primary: Box and Blocks Test (BBT) Score Across the 12 Weeks of the Intervention, Immediately After Conclusion of Intervention, and 3 Months Post-intervention — 13.74; 21; 19.67…

Primary: Numerical Rating Scale (NRS) Pain on Walking — -3.84 units on a scale — p=<0.0001

Primary: Number of Participants With Any Gastrointestinal (GI) Symptoms — 1; 1 Participants